GC Therapeutics | Series ASep 2024$65M | $65M |
Co-investors: Hiroki Takai (Global Brain) |
Rejuveron Life Sciences | Series BSep 2023$75M | $75M |
EpiBiologics | Series AMar 2023$73M | $96M |
Co-investors: David Schenkein (GV (Google Ventures)), Alexandra Cantley (Polaris Partners), Samuel Bjork (Digitalis Ventures) |
Paradigm | Series AJan 2023$200M | $240M |
Co-investors: Elena Viboch (General Catalyst), Ramnik Arora (FTX Ventures), Hemant Taneja (General Catalyst), Bilal Zuberi (Lux Capital), Brett Cook (F-Prime Capital Partners), Stephen Knight (F-Prime Capital Partners), Jay Markowitz (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners), Jared Friedman (Y Combinator), Scott Belsky, Eoghan McCabe, Arash Ferdowsi |
UpStream Care | Series BDec 2022$140M | $140M |
Co-investors: Eric Jones (Dragoneer Investment Group), Chirag Shah (Define Ventures), Lynne Chou O’Keefe (Define Ventures), Ayman AlAbdallah |
Neumora Therapeutics | Series B Oct 2022 $110M | $510M |
Co-investors: Stacie Weninger (F-Prime Capital Partners), Robert Nelsen (ARCH Venture Partners), Kristina Burow (ARCH Venture Partners) |
Alloy Therapeutics | Series D Oct 2022 $42M Series CApr 2021$75M | $130M |
Co-investors: Alex Kolicich (8VC), Peter Thiel (Founders Fund), Fabian Hansen (Presight Capital) |
Pretzel Therapeutics | Series ASep 2022$73M | $73M |
Co-investors: Per Samuelsson (HealthCap), Robert Tansley (Cambridge Innovation Capital), Jay Parrish (ARCH Venture Partners), Reetika Bhardwaj (ARCH Venture Partners), Kristina Burow (ARCH Venture Partners) |